Longevity medicine's do-or-die moment
Summary
A new clinical trial is testing a gene therapy that may make human cells younger by partially reprogramming them. This trial focuses on treating eye diseases like glaucoma and will first check if the therapy is safe for humans.Key Facts
- The trial is the first in humans to test if cells can be made younger through "cellular reprogramming."
- The therapy targets three genes to restore nerve function between the eye and the brain.
- Life Biosciences, co-founded by Harvard professor David Sinclair, is sponsoring the trial.
- The current trial only tests safety, not if the therapy can slow aging or cure glaucoma.
- Success could prove the concept of cellular reprogramming as a way to treat aging.
- Longevity biotech companies have attracted hundreds of millions of dollars in investments.
- Some major investors include tech billionaires like Coinbase CEO Brian Armstrong and OpenAI CEO Sam Altman.
- Longevity research aims to treat aging as a biological process that might be changed by medicine.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.